Abstract submission

Abstract submission is closed. In July it will be possible to submit ‘Late breaking abstracts’

Please note the terms and conditions before submitting an abstract:

• Abstracts need to be submitted via the online submission portal by the deadline of Monday 1 April, 2024 (23:59, CET). Abstracts submitted by post, fax or email will not be considered.
• The submitting author is required to ensure that all co-authors are aware of the content of the abstract before submission.
• Content needs to relate to not previously published results.
• The submitting author will act as the main point of contact for the abstract with organizers.
• Submission of an abstract automatically implies acknowledgement by the submitting author that the work described was conducted in accordance with current ethical standards and regulations in medical research.
• Abstracts should be submitted and presented in English.
• Changes to an abstract will not be permitted once the submission deadline has passed.
• Abstracts will be reviewed by the International Scientific Committee. Abstracts which include ethical concerns, do not meet scientific standards or include work not sufficiently relevant for FTD can be rejected. Notification regarding abstract acceptance and scheduling will be sent to the submitting author by email.
• All abstracts accepted for presentation will be published via the Conference website www.isftd2024.org
• Please note that the presenting author is not automatically registered by submitting an abstract.
• Non-registered authors will not be permitted to present their work at the conference. Only accepted abstracts with a presenting author registered with will be included for publication. When notified of acceptance, the Presenting Author is required to accept the offer by registering for the conference and paying in full by 30 June 2024.

• We would like to invite you to submit an abstract that contributes to the conference topics defined.
• Epidemiology: (e.g. Geographical distribution, risk factors, environmental factors, sex-differences, etc.)
• Biomarkers (fluid / neuroimaging): (e.g. Differential diagnosis FTD vs psychiatric disease, proteinopathy-specific biomarkers, neuroimaging advances, etc.)
• Neuropsychology: (e.g. Remote-assessment, biometrics, digital testing, memory disturbances in FTD)
• Neuropsychiatry: (e.g. criminal behavior, psychiatric symptoms in FTD, phenocopy syndrome, terminology, schizophrenia, addiction, etc.)
• Genetics: (e.g. Functional analysis of GWAS-results, novel mutations, genetic modifiers, disease modeling, etc)
• Clinic: (e.g. Clinical subtypes, atypical presentations, video-presentations, bedside tools, etc)
• Diversity: (e.g. ethnic, genetic, linguistic, cultural, etc)
• Clinical trials: (e.g. preclinical pharmaceutical studies, outcome measures, trial design)
• Management: (e.g. caregiver perspectives, symptomatic treatment, behavioural management, etc)
• Translational research: (e.g. Bioinformatics, AI/big-data/machine learning, single-cell approaches, multi-omics, pathogenesis, connectomics, etc.)
• Neuropathology: (e.g. Cryo-EM, TDP biology, vascular factors, glial cells, etc.)
• Sporadic FTD: (e.g. Cohorts, environmental factors, inflammatory factors, demographics, etc)
• Pathophysiological mechanisms: (e.g. Fundamental research, organoids, iPSC’s, proteostasis, synaptic function, splicing mechanisms, disease spreading, etc.